|
FY2022
12 months to Mar 31, 2022
|
FY2021
12 months to Mar 31, 2021
|
FY2020
12 months to Mar 31, 2020
|
FY2019
12 months to Mar 31, 2019
|
FY2018
12 months to Mar 31, 2018
|
|
|---|---|---|---|---|---|
| Net loss | |||||
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation | |||||
| Amortization of employees, directors and consultants stock options | |||||
| Change in fair value of warrant liability | |||||
| Net amortization of premiums and discounts on marketable securities | |||||
| Loss on call redemption of marketable securities | |||||
| Change in operating assets and liabilities: | |||||
| Prepaid clinical costs | |||||
| Prepaid expenses and other assets | |||||
| Operating lease right-of-use asset | |||||
| Accounts payable and other current liabilities | |||||
| Severance payable | |||||
| Accrued bonuses | |||||
| Operating lease liability | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of marketable securities | |||||
| Proceeds from maturities of marketable securities | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Insurance note payments | |||||
| Proceeds from registered offerings, net of issuance costs | |||||
| Proceeds from exercise of stock options | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash | |||||
| Cash and cash equivalents — beginning of year | |||||
| Cash and cash equivalents — end of year | |||||
| Supplemental Cash Flow Information: | |||||
| Cash paid for interest and income taxes are as follows: | |||||
| Interest | |||||
| Noncash investing and financing activities: | |||||
| Financing of insurance premiums | |||||
| Operating lease right-of-use asset obtained in exchange for lease liabilities | |||||
Loading...